Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 12/20 | 0.53 |
| ▸ | KDR | P35968 | 12/20 | 0.53 |
| ▸ | KIF5B | P33176 | 9/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | RAF1 | P04049 | 2/20 | 0.49 |
| ▸ | BRAF | P15056 | 2/20 | 0.49 |
| ▸ | SRC | P12931 | 3/20 | 0.49 |
| ▸ | FLT1 | P17948 | 2/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.48 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.47 |
| ▸ | FLT4 | P35916 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5218965 | 0.84 | KDR (0.63) | RETKDRKIF5BEGFRRAF1 | |
| SCHEMBL5220271 | 0.82 | SRC (0.66) | RETKDRKIF5BEGFRRAF1 | |
| SCHEMBL13485425 | 0.80 | KDR (0.63) | RETKDRKIF5BEGFRRAF1 | |
| SCHEMBL7574688 | 0.75 | SRC (0.83) | RETKDRKIF5BEGFRRAF1 | |
| SCHEMBL2138123 | 0.75 | KDR (0.69) | RETKDRKIF5BEGFRRAF1 | |
| SCHEMBL1467058 | 0.74 | KDR (0.83) | RETKDRKIF5BEGFRRAF1 | |
| SCHEMBL7118883 | 0.74 | SRC (0.74) | RETKDRKIF5BEGFRRAF1 | |
| SCHEMBL3958826 | 0.72 | EGFR (0.62) | RETKDRKIF5BEGFRRAF1 | |
| SCHEMBL5242610 | 0.72 | KDR (0.81) | RETKDRKIF5BEGFRRAF1 | |
| SCHEMBL6018368 | 0.72 | EGFR (0.68) | RETKDRKIF5BEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014773-A1 | Therapeutic use | ASTRAZENACA AB (SE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014773-A1 | Therapeutic use | CD4, HLA-DRB1, CD74 | RET 2808/4885KDR 2580/4885KIF5B 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.